MFN · company-page
MFN bolagssida och bolagsmetadata
10515 tecken · 1 HTML-del(ar)
Fulltext
MFN.se > Alvotech Pressmeddelanden Om oss Kontakt Privacy Policy Login Logga in med X Login Inställningar Split view Short keys for navigating in split view ↑ Select newer press release ↓ Select older press release ← Navigate backwards → Navigate forward Enter Navigate to line in focus Tab Focus next link A or 1 Open First attachment S or 2 Open Second attachment D or 3 Open Third attachment F or 4 Open Fourth attachment I Show company information PgUp Select newest press release PgDown Select oldest press release L Focus on filer bar N Increase preview window size M Decrease preview window size Esc Escape from mode Dark Mode Set dark mode to MFN.se Sound Plays a notification sound when new press release is published in the current feed Intresserad av platformen MFN för nyhetsdistribution? Läs mer Boka demo Logga in som bolag Måndag 3 Augusti | 18:41:47 Europe / Stockholm Svenska | English Alvotech Kalender Est. tid* 2027-03-11 N/A Bokslutskommuniké 2026 2026-11-12 22:30 Kvartalsrapport 2026-Q3 2026-08-20 22:30 Kvartalsrapport 2026-Q2 2026-05-08 - X-dag ordinarie utdelning ALVO 0.00 ISK 2026-05-07 - Kvartalsrapport 2026-Q1 2026-03-19 - Bokslutskommuniké 2025 2025-11-12 - Kvartalsrapport 2025-Q3 2025-08-14 - Kvartalsrapport 2025-Q2 2025-06-26 - X-dag ordinarie utdelning ALVO 0.00 ISK 2025-06-25 - Årsstämma 2025-05-08 - Kvartalsrapport 2025-Q1 2025-03-26 - Bokslutskommuniké 2024 2024-11-14 - Kvartalsrapport 2024-Q3 2024-08-16 - Kvartalsrapport 2024-Q2 2024-05-22 - Kvartalsrapport 2024-Q1 2024-03-20 - Bokslutskommuniké 2023 2023-11-14 - Kvartalsrapport 2023-Q3 2023-08-17 - Kvartalsrapport 2023-Q2 2023-06-06 - Årsstämma 2023-05-19 - Kvartalsrapport 2023-Q1 Beskrivning Land Island Lista Large Cap Iceland Sektor Hälsovård Industri Medicinteknik Alvotech är ett bioteknikbolag som fokuserar på utveckling och tillverkning av biosimilära läkemedel. Bolagets pipeline består av biosimilar-kandidater som syftar till att behandla autoimmuna sjukdomar, ögonsjukdomar, osteoporos och cancer. Bolaget erbjuder sina produkter till patienter över hela världen. Alvotech grundades år 2013 och har sitt huvudkontor i Reykjavík. Intresserad av bolagets nyckeltal? Analysera bolaget i Börsdata ! Vem äger bolaget? All ägardata du vill ha finns i Holdings ! Filter År Typ Språk Rensa Språk Använd filter Rensa Se endast PM som skrivits på följande språk Engelska Svenska Tyska Isländska Typ Använd filter Rensa Finansiella rapporter År Använd filter Rensa Se endast PM som skrivits från valt år 2026 2025 2024 2023 2022 Språk Använd filter Rensa Se endast PM som skrivits på följande språk Engelska Svenska Tyska Isländska Typ Använd filter Rensa Finansiella rapporter 2026-07-29 15:32:10 Alvotech tilkynnir að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hefur lokið úttekt sinni á framleiðsluaðstöðu félagsins 445,00 ISK | +14,40% 2026-07-29 15:32:10 Alvotech announces successful closure of FDA inspection of manufacturing facility 445,00 ISK | +14,40% 2026-07-29 15:25:48 Alvotech announces successful closure of FDA inspection of manufacturing facility 445,00 ISK | +14,40% 2026-07-03 22:01:00 Transactions of Managers and Closely Associated Persons 2026-07-03 22:01:00 Viðskipti stjórnenda og tengdra aðila 2026-07-01 10:00:00 Alvotech styrkir lausafjárstöðu sína enn frekar með aðgengi að 75 milljóna dala lánsfjármögnun 470,00 ISK | -1,26% 2026-07-01 10:00:00 Alvotech further strengthens liquidity by securing term loan facility of $75 million 470,00 ISK | -1,26% 2026-07-01 10:00:00 Alvotech further strengthens liquidity by securing term loan facility of $75 million 470,00 ISK | -1,26% 2026-06-23 00:48:04 Viðskipti stjórnenda og tengdra aðila 466,00 ISK | -3,92% 2026-06-23 00:48:04 Transactions of Managers and Closely Associated Persons 466,00 ISK | -3,92% 2026-06-18 11:51:56 Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement 485,00 ISK | -2,41% 2026-06-18 10:00:00 Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares 485,00 ISK | -2,41% 2026-06-18 10:00:00 Hlutafjárútboði Alvotech í Bandaríkjunum lokið og umsjónaraðilar nýttu sér að fullu kauprétt á viðbótarbréfum svo heildarandvirði að meðtöldum hlutum keyptum af evrópskum fagfjárfestum nemur 165 milljónum dollara 485,00 ISK | -2,41% 2026-06-18 10:00:00 Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement 485,00 ISK | -2,41% 2026-06-16 05:59:58 Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement 497,00 ISK | -6,23% 2026-06-16 05:50:00 Alvotech tilkynnir um verð og úthlutun hlutabréfa að andvirði um 152 milljónir dollara í útboði í Bandaríkjunum og lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu 497,00 ISK | -6,23% 2026-06-16 05:50:00 Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement 497,00 ISK | -6,23% 2026-06-15 22:01:00 Alvotech efnir til útboðs á hlutabréfum í Bandaríkjunum að andvirði 125 milljónir dollara samhliða lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu 497,00 ISK | -6,23% 2026-06-15 22:01:00 Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares 497,00 ISK | -6,23% 2026-06-15 22:01:00 Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares 497,00 ISK | -6,23% 2026-06-10 22:30:00 Viðskipti stjórnenda og tengdra aðila 534,50 ISK | +4,39% 2026-06-10 22:30:00 Transactions of Managers and Closely Associated Persons 534,50 ISK | +4,39% 2026-06-08 10:00:00 Matvæla- og lyfjastofnun Bandaríkjanna tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir AVT16, fyrirhugaða hliðstæðu við Entyvio 493,00 ISK | +9,80%  | 41,0 MISK 2026-06-08 10:00:00 Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® 493,00 ISK | +9,80%  | 41,0 MISK 2026-06-08 10:00:00 Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® 493,00 ISK | +9,80%  | 41,0 MISK 2026-06-04 10:00:00 Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® 452,00 ISK | +22,00%  | 23,6 MISK 2026-06-04 10:00:00 Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® 452,00 ISK | +22,00%  | 23,6 MISK 2026-06-04 10:00:00 Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea 452,00 ISK | +22,00%  | 23,6 MISK 2026-06-03 22:30:00 Main Results of 2026 Annual and Extraordinary General Meeting 452,00 ISK | +22,00%  | 23,6 MISK 2026-06-03 22:30:00 Niðurstaða aðalfundar Alvotech árið 2026 452,00 ISK | +22,00%  | 23,6 MISK 2026-06-03 22:30:00 Main Results of 2026 Annual and Extraordinary General Meeting 452,00 ISK | +22,00%  | 23,6 MISK 2026-06-02 22:30:00 Alvotech tekur þátt í þremur fjárfestaráðstefnum í Bandaríkjunum í júní 370,50 ISK | -4,76%  | 11,1 MISK 2026-06-02 22:30:00 Alvotech to present at upcoming investor conferences in June 370,50 ISK | -4,76%  | 11,1 MISK 2026-06-02 22:30:00 Alvotech to present at upcoming investor conferences in June 370,50 ISK | -4,76%  | 11,1 MISK 2026-06-01 10:30:00 Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland 408,00 ISK | -3,77%  | 3,02 MISK 2026-06-01 10:30:00 Alvotech og Íslandsbanki endurnýja samning um viðskiptavakt með bréf félagsins í Kauphöllinni 408,00 ISK | -3,77%  | 3,02 MISK 2026-05-11 10:30:00 Matvæla- og lyfjaeftirlit Bandaríkjanna lýkur úttekt á framleiðsluaðstöðu Alvotech 440,00 ISK | +13,40%  | 13,4 MISK 2026-05-11 10:30:00 Alvotech announces completion of FDA surveillance inspection at Reykjavik facility 440,00 ISK | +13,40%  | 13,4 MISK 2026-05-11 10:30:00 Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility 440,00 ISK | +13,40%  | 13,4 MISK 2026-05-06 22:30:00 Alvotech Q1 2026 Financial Results 392,00 ISK | -10,91%  | 44,6 MISK 2026-05-06 22:30:00 Alvotech Q1 2026 Financial Results 392,00 ISK | -10,91%  | 44,6 MISK 2026-05-06 22:30:00 Alvotech birtir uppgjör fyrsta ársfjórðungs 2026 392,00 ISK | -10,91%  | 44,6 MISK 2026-04-30 22:30:00 Alvotech Announces a Change in its Executive Team 2026-04-30 22:30:00 Alvotech tilkynnir breytingu í framkvæmdastjórn 2026-04-30 22:30:00 Alvotech Announces a Change in its Executive Team 2026-04-24 14:30:00 Alvotech to Report Financial Results for the First Quarter of 2026 422,00 ISK | -3,43%  | 11,6 MISK 2026-04-24 14:30:00 Alvotech birtir uppgjör fyrsta ársfjórðungs 2026 þann 6. maí nk. 422,00 ISK | -3,43%  | 11,6 MISK 2026-04-24 14:30:00 Alvotech to Report Financial Results for the First Quarter of 2026 422,00 ISK | -3,43%  | 11,6 MISK Visa fler Enter your email address and you will get a mail for verification you subscription to content on this page and filter Email Prenumerera Det måste ange en riktig mailadress Ett verifikationsmail har skickats till adressen Select the time zone location for site wide time Timezone Europe London Oslo Stockholm Helsinki America New York / Eastern Chicago / Central Los Angeles / Western Change Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto Företag Pressmeddelanden Den här websidan använder cookies för att ge dig den bästa upplevelsen av sidan. Läs mer Acceptera cookies MFN - en produkt från Hemsida Karriär LinkedIn